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Abstract
Background: Endothelial progenitor cells (EPCs) are implicated in a range of pathological conditions, suggesting a
natural therapeutic role for EPCs in angiogenesis. However, current angiogenic therapies involving EPC
transplantation are inefficient due to rejection of donor EPCs. One solution is to derive an expanded population of
EPCs from stem cells in vitro, to be re-introduced as a therapeutic transplant. To demonstrate the therapeutic
potential of EPCs we performed in vitro transplantation of EPCs into endothelial cell (EC) tubules using a gel-based
tubule formation assay. We also described the production of highly angiogenic EPC-comparable cells from
pluripotent embryonic stem cells (ESCs) by direct differentiation using EC-conditioned medium (ECCM).
Results: The effect on tubule complexity and longevity varied with transplantation quantity: significant effects were
observed when tubules were transplanted with a quantity of EPCs equivalent to 50% of the number of ECs
originally seeded on to the assay gel but not with 10% EPC transplantation. Gene expression of the endothelial
markers VEGFR2, VE-cadherin and CD31, determined by qPCR, also changed dynamically during transplantation.
ECCM-treated ESC-derived progenitor cells exhibited angiogenic potential, demonstrated by in vitro tubule
formation, and endothelial-specific gene expression equivalent to natural EPCs.
Conclusions: We concluded the effect of EPCs is cumulative and beneficial, relying on upregulation of the
angiogenic activity of transplanted cells combined with an increase in proliferative cell number to produce
significant effects upon transplantation. Furthermore, EPCs derived from ESCs may be developed for use as a
rapidly-expandable alternative for angiogenic transplantation therapy.
Background
In the early embryo, mesodermal stem cells in the bone
marrow (BM) differentiate to form haemangioblasts, the
common precursor of haematopoietic stem cells and
endothelial-lineage angioblasts [1,2]. During vasculogen-
esis these immature but lineage-committed angioblasts,
termed endothelial progenitor cells (EPCs), migrate and
congregate into clusters, called blood islands, forming
the primary vascular plexus from which a complex
microcirculation arises [3,4]. In contrast, adult vascular
growth occurs primarily through angiogenesis whereby
new capillaries develop endogenously from fully-differ-
entiated endothelial cells (ECs) within existing vessels
[5]. However, angiogenesis is not the sole mechanism by
which the adult vasculature is augmented [6,7].
Circulating EPCs share phenotypic characteristics with
embryonic EPCs [8] and incorporate into sites of neo-
vascularisation, suggesting a role for EPCs in angiogenic
renewal [9,10]. They express endothelial-specific mar-
kers, including vascular endothelial growth factor recep-
tor 2 (VEGFR2), CD31, CD133, VE-cadherin and von
Willebrand factor (vWF), which have various roles in
cell-cell adhesion, vascular permeability and the modula-
tion of other cellular responses during angiogenesis
[11,12]. Indeed, EPCs are implicated in angiogenesis sti-
mulated by conditions such as coronary artery disease
and myocardial infarction, confirmed by clinical obser-
vations of EPC mobilisation in such patients and incor-
poration into foci of pathological neovascularisation
[13,14].
Nevertheless, current approaches to angiogenic thera-
pies are problematic. Endogenous approaches most
likely rely on the recruitment of circulating EPCs, and
the delivery of a single pro-angiogenic substance is
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insufficient to elicit the complete and prolonged
response necessary for effective angiogenesis [15,16].
Exogenous therapies involve administration of allogeneic
donor EPCs, which with poor HLA matching leads to
increased immune rejection resulting in reduced trans-
plantation efficiency [17,18]. Consequently, the use of an
expanded population of autologous EPCs from the
patient’s own adult stem cell population is desirable.
In contrast to EPCs, the inner cell mass of blastocyst-
stage embryos gives rise to a population of self renewing
pluripotent, embryonic stem cells (ESCs) [19], which are
precursors to all cell types of the body [20]. Whilst
potential ethical considerations must be considered, such
as the use of otherwise viable human embryos for cell
harvesting, the capacity of ESCs for unlimited growth
may allow rapid in vitro expansion and differentiation,
producing endothelial-like cells for transplantation. Dif-
ferentiation can be induced either spontaneously or
directed specifically towards the endothelial lineage using
EC-conditioned medium (ECCM). This medium would
require specific growth factors, such as VEGF, basic
fibroblast growth factor (bFGF), epidermal growth factor
(EGF), interleukin-6 and erythropoietin to promote dif-
ferentiation [21-23].
Chemical stimuli may, at least in part, drive the
response of EPCs during angiogenesis. These stimuli
can be released from surrounding tissues, i.e. from
within the microenvironment, or from the endothelial
cells themselves. Indeed, it has been shown in hypoxic
wounds of diabetic patients that EPCs in the BM
respond by following chemokine gradients, resulting in
their homing to sites of hypoxia where they can partici-
pate in neovascularisation [24]. Consequently, the
microenvironment in which progenitor cells are cultured
is critical to their ability to maintain their progenitor
status, i.e. to self-renew and give rise to differentiated
cell types as and when recruited to do so. For instance,
it has been shown that under the appropriate microen-
vironmental cues, achieved by using a combination of in
vitro culture supplements, cord blood-derived precursor
cells are able to give rise to cells characteristic of EPCs
[25]. Furthermore, specific Notch signals within the BM
microenvironment have been demonstrated to be vital
for EPC-mediated vasculogenesis through murine
knockout models of hindlimb ischaemia [26].
Although the remodelling of mature ECs during the
development of endothelial tubules in vitro is well
understood, the mechanism of EPC involvement
remains unclear. In vitro assays are able to model the in
vivo microenvironment, and those cues specific to
angiogenesis enable us to understand how related cell
types form tubules and networks of branches. They also
allow us to ascertain the concomitant expression of line-
age-specific genes during development and tissue repair.
For example, it has been shown that ECs form organised
tubule networks when cultured on glycoprotein-rich
matrices containing angiogenesis-stimulating growth fac-
tors [27], and their potential to form pseudo-vessels can
be demonstrated using an in vitro gel-based assay [28].
Here, we have determined, in a time-dependent manner,
how EPCs form tubule networks in vitro using an
ECMatrix gel. We then showed how ESCs are able to
mimic this outcome when cultured in a defined medium
to promote EPC differentiation. We also demonstrated
that EPCs transplanted into gel-based cultures of ECs
that have begun to exhibit tubule loss and reduced net-
work density can rescue tubule formation, by generating
new tubules rather than incorporating into existing
tubules.
Methods
Cell lines and culture media
The murine EC line MCEC-1 was provided by Prof.
Gerard Nash (University of Birmingham, UK). The mur-
ine EPC line MFLM-4 was obtained from Seven Hills
Bioreagents (Ohio, US). Endothelial growth medium
consisted of Dulbecco’s modified Eagle medium
(DMEM) with 10% fetal bovine serum (FBS), 1% penicil-
lin-streptomycin and 2 mM L-glutamine, supplemented
with 10 U·ml-1 heparin and 0.1 μg·ml-1 recombinant
murine epidermal growth factor (EGF) (for MCEC-1) or
25 mg·ml-1 amphotericin B and 10 ng·ml-1 basic fibro-
blast growth factor (bFGF) (for MFLM-4). ESCs derived
from blastocysts of 129S2/SvPas mice (D3) were
obtained from American Type Culture Collection
(ATCC, Middlesex, UK). ESC growth medium consisted
of Knockout DMEM (Invitrogen, Paisley, UK) contain-
ing 15% ESC-Screened FBS (HyClone; Thermo Fisher,
Leicestershire, UK), 1% penicillin-streptomycin, 2 mM
L-glutamine, 1% non-essential amino acids, 0.1 mM b-
mercaptoethanol and 10 ng·μl-1 recombinant murine
leukemia inhibitory factor (LIF) (Chemicon, Livingston,
UK). Undifferentiated ESCs were maintained on CF-1
murine embryonic fibroblast feeder cells (ATCC) mitoti-
cally-inactivated by treatment with 10 μg·ml-1 mitomy-
cin C for 2 h at 37°C.
Differentiation of stem cells
ESCs were spontaneously differentiated using the hang-
ing droplet method [29]. Undifferentiated cells (D0)
were resuspended in growth medium (minus LIF) and
plated as 20 μl droplets (450 cells/drop) on Petri dishes.
Inverted dishes were incubated at 37°C/5% CO2 for 48
hours (D1-2) to induce embryoid body (EB) formation.
EBs were then grown in suspension for 5 days (D3-7).
For directed differentiation, cells were resuspended in
ECCM for D3-7; ECCM was produced by 24 h incuba-
tion with MCEC-1 cells.
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Lectin staining and uptake of acetylated (ac-)LDL
EPCs and ECs were incubated with 0.5 mg·ml-1 fluores-
cein-conjugated Griffonia (Bandeiraea) simplicifolia lec-
tin I (Vector Laboratories Inc., California, USA) in PBS
for 1 h at 37°C, and 10 μg·ml-1 of 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DiI)-
labelled ac-LDL in culture medium for 4 h at 37°C.
In vitro tubule formation assay
Angiogenic activity of cells was assessed using the In
vitro Angiogenesis Assay Kit (Chemicon). For each
assay, 3 μl Diluent Buffer was added to 27 μl ECMatrix
Gel Solution and polymerized on an 18 mm glass cov-
erslip by incubation at 37°C for 30 minutes. Cells were
seeded at a density of 8 × 104 cells/coverslip in 400 μl
growth medium and returned to the incubator for
14 h. Images were recorded every 2 h for tubule
quantification.
In vitro EPC transplantation
Transplantation was performed by addition of EPCs into
a tubule formation assay containing ECs. Prior to trans-
plantation, EPCs were labelled using 5 mM Qtracker
655 quantum dot (Qdot) labelling solution (Invitrogen,
Paisley, UK) according to manufacturer’s instructions.
To investigate the effect of cell number on transplanta-
tion two quantities of EPCs were used, equivalent to
10% (8 × 103 cells) or 50% (4 × 104 cells) of the number
of ECs originally seeded. At 5 h, a suspension of 10% or
50% Qdot-labelled EPCs in 50 μl PBS was pipetted
evenly over the EC-containing ECMatrix gel and the
coverslip was returned to the incubator.
Quantification of in vitro tubule formation
Tubule formation was quantified by counting nodes,
points at which branches intersect, and measuring
branch lengths. Nodes were graded based on structure:
branch end-points as N1; intersections as N2; junctions
of three or four branches as N3 or N4; and nodes of
five or more branches as N5+. The average number of
each node type was calculated based on five fields of
view every 2 h. Branch length was measured using
AQuaL Angiogenesis Quantification software [30].
Tubule images were tagged with markers, defined as
end-points or junctions, and overall lengths automati-
cally calculated based on five fields of view.
Gene expression analysis
Cells were recovered from ECMatrix gel using Cell
Recovery Solution (BD Biosciences, Oxford, UK). Total
RNA was isolated using RNAqueous-4PCR Kit (Ambion,
Warrington, UK) followed by decontamination with
DNase I (Ambion). Reverse transcription was performed
using MMLV reverse transcriptase (Bioline, London,
UK) with Oligo (dT)18 primers to produce complemen-
tary DNA (cDNA). cDNA was used for quantitative
real-time PCR (qPCR) performed in a Corbett Rotor-
Gene 3000 cycler (QIAGEN, West Sussex, UK) using
SYBR Green chemistry. Each qPCR reaction (25 μl final
volume) consisted of 1 μl cDNA template, 12.5 μl Quan-
tace SensiMix (Bioline, London, UK), 0.5 μl 50× SYBR
Green I Solution (Bioline), 0.2 μM each of forward and
reverse primers (Invitrogen) and PCR-grade H2O. A 270
bp product of VEGFR2 cDNA was amplified with
VEGFR2-F (5’- TCTGTGGTTCTGCGTGGAGA-3’) and
VEGFR2-R (5’-GTATCATTTCCAACCACCCT-3’); a
244 bp product of CD31 cDNA was amplified with
CD31-F (5’-CGCACCTTGATCTTCCTTTC-3’) and
CD31-R (5’-AAGGCGAGGAGGGTTAGGTA-3’); a 122
bp product of VE-cadherin cDNA was amplified with
VE-cadherin-F (5’-TCCTCTGCATCCTCACCATCACA-
3’) and VE-cadherin-R (5’- GTAAGTGACCAACT
GCTCGTGAAT-3’); and a 242 bp product of b-actin
cDNA was amplified with b-actin-F (5’-CACCA-
CACCTCCTACAATGAGC-3’) and b-actin-R (5’-
TCGTAGATGGGCACAGTGTGGG-3’). Initial dena-
turation was performed at 95°C for 15 minutes, followed
by 50 cycles of: denaturation at 95°C for 10 seconds;
annealing at 55°C (VEGFR2 and CD31) or 57°C (VE-
cadherin and b-actin) for 15 seconds; and extension at
72°C for 15 seconds. A range of known standards (2
ng·μl-1 to 2 × 10-9 ng·μl-1) of each PCR product were
generated to enable quantification of gene expression,
with the housekeeping gene b-actin used as a calibrator
for relative quantification.
Immunocytochemistry (ICC)
Cells were fixed using 4% paraformaldehyde and non-
specific blocking performed using 2% bovine serum
albumin, 100 mM glycine and 0.2 mg·ml-1 sodium azide
for 30 minutes at room temperature. Primary antibodies
included VEGFR2 (goat, 4 μg·ml-1), CD133 (rabbit, 2
μg·ml-1) and CD34 (rat, 5 μg·ml-1) (Abcam, Cambridge,
UK). Secondary antibodies included anti-goat conjugated
to Alexa Fluor (AF) 488 (rabbit; 1:400), anti-rabbit (AF
594, donkey; 1:500) and anti-rat (AF 594, chicken;
1:400) (Molecular Probes; Invitrogen). Coverslips were
mounted using Vectorshield DAPI Mounting Medium
(Vector Laboratories Inc., Peterborough, UK). Micro-
scopy was performed using a Zeiss 510 Meta confocal
microscope (Carl Zeiss Ltd., Hertfordshire, UK) with
×63 oil DIC objective (NA 1.4) with the detection pin-
hole adjusted to 1 Airy unit. DAPI was excited at 360
nm and detected at 460 nm, Alexa Fluor (AF) 488 was
excited at 488 nm and detected between 515-545 nm,
and AF 594 was excited at 594 nm and detected at 617
nm. Qdot-labelled EPCs were visualized by excitation
between 405-615 nm and detection at 655 nm.
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Statistical methods
Statistical differences were calculated using one-way
ANOVA and post hoc multiple comparisons using the
Bonferroni test.
Results
Endothelial-specific gene expression is dynamic during
lineage development
Highly-confluent cells, including the endothelium,
demonstrate a reduced response to specific growth fac-
tors and proliferative signals such as VEGF [31,32] and
contact inhibition is thus implicated as an important
endothelial anti-proliferative mechanism. Hence, to
determine the effect of contact inhibition on endothe-
lial-specific expression, we analysed the patterns of
expression of three key endothelial markers, VEGFR2,
VE-cadherin and CD31 in MFLM-4 EPCs and MCEC-1
ECs cultured at 60%, 80% and 100% confluency. Both
cell types expressed all three markers at each stage of
confluency, though with significant differences whereby
increased confluency, and thus contact inhibition,
resulted in significant overall decreases in expression (P
< 0.01). To this extent, the relative expression of
VEGFR2 was significantly greater at 60% and 80% con-
fluency in EPCs than ECs (P < 0.05; Figure 1a). Expres-
sion in EPCs increased, though non-significantly, as
culture confluency increased from 60% to 80%, whilst
no difference in expression was observed between 60%
and 80% confluent ECs. Relative expression of VE-cad-
herin was significantly higher in 60% confluent ECs than
in the other cells analyzed (P < 0.05; Figure 1b) and
decreased with confluency. VE-cadherin expression in
EPCs increased between 60% and 80% confluency.
Expression of CD31 was greatest in 60% confluent EPCs
but reduced as EPCs became 80% confluent (Figure 1c).
CD31 expression was also not significantly different
between 60% and 80% confluent ECs. Through ICC
staining, we were able to confirm expression of
VEGFR2, CD133 and CD34 proteins in EPCs (Figure
1d) and ECs (Figure 1e) with little evidence for change
with degree of confluency.
Further to the characterisation of the chosen cell lines
by gene expression analysis, the endothelial phenotypes
of MFLM-4 EPCs and MCEC-1 ECs was demonstrated
by endothelial-specific lectin staining and uptake of DiI-
labelled ac-LDL (Figure 1f).
EPCs and ECs demonstrate angiogenic potential by in
vitro tubule formation
To determine whether EPCs and ECs possessed angio-
genic potential, and were thus able to form endothelial
tubules, we cultured both cell types individually on
ECMatrix gel for 14 h. Tubule formation was quanti-
fied by node counting and branch length measurement.
The mean number of each node type at each time-
point throughout the assay was similar for EPCs and
ECs (P > 0.05; Figure 2a and 2b, respectively). A large
number of N1 nodes was observed at 2 h, decreasing
as the assay progressed, resulting in the formation of
more N2 and N3 nodes and thus more complex struc-
tures. These were maximal at 4 h and 6 h, respectively
for both cell lines. After 6 h, the number of N2 and
N3 nodes decreased and they were last evident
between 10 h and 12 h. Nevertheless, this gave rise to
the formation of more complex structures, N4 nodes,
which were first observed at 4 h for both EPCs and
ECs and reached a maximum at 6 h and persisted
until 8 h (ECs) and 10 h (EPCs) (P < 0.05). In turn,
the most complex nodal formation (N5+) was first evi-
dent in EPC colonies between 6 to 8 h whilst ECs did
not produce these structures. However, no tubule net-
works were observed after 12 h for either EPCs or
ECs. The pattern of tubule formation indicated by
branch length measurement was also similar for EPCs
and ECs (Figure 2c). Mean length increased for both
cell types from 0 to 6 h with maximal branch length
being at 6 h, although mean length of EPC tubules at
6 h was significantly greater (P < 0.01). Nevertheless,
mean branch length then decreased with significantly
lower length being observed for ECs at 8 h (P < 0.05)
when compared to EPCs. Thereafter, mean branch
length continued to decrease for both cell types.
To determine whether tubule formation from EPCs
and ECs was a function of endothelial-specific expres-
sion, we analyzed VEGFR2, VE-cadherin and CD31
expression. VEGFR2 expression increased in both cells
from 0 h to 2 h, with a significantly greater level in
EPCs at 0 h (P < 0.05) and 2 h (P < 0.01; Figure 3a)
whilst maximal expression was observed at 2 h and 4 h
for EPCs and ECs, respectively, followed by a progres-
sive decrease. From 0 h to 6 h, ECs expressed signifi-
cantly more VE-cadherin than EPCs and, following an
initial decrease between 0 h and 2 h in EPCs, expression
progressively increased up to 8 h (P < 0.05; Figure 3b).
Expression in ECs reached its maximum by 4 h (P <
0.05) and then decreased from 4 h onwards whilst in
EPCs this started at 8 h, there being no significant dif-
ference between EPCs and ECs from this point onwards.
Expression of CD31 in EPCs increased from 0 h to 4 h
(P < 0.05) followed by a reduction at 6 h (P < 0.05; Fig-
ure 3c). Conversely, CD31 expression in ECs decreased
from 0 h to 4 h before increasing to its maximum at 6
h, whilst in EPCs maximal expression was observed at 8
h (P < 0.05). After 8 h, expression in both cell types
decreased progressively.
In order to confirm that EPCs were able to develop
into fully differentiated cells as they contributed to
tubule formation, we analysed the number of
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Figure 1 Characterization of EPCs and ECs. qPCR of (A) VEGFR2, (B) VE-cadherin and (C) CD31 expression at increasing confluency, relative to
60% confluent ECs (mean ± SEM; n = 3). Columns with different letters are significantly different (P < 0.05). ICC of VEGFR2, CD133 and CD34 in
(D) EPCs and (E) ECs. Scale bar = 30 μm. (F) Uptake of DiI-ac-LDL (red) and staining with lectin (green). Nuclear staining (blue) with DAPI-
containing mounting medium.
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mitochondrial (mt)DNA copies over the 14 h assay per-
iod. This is indicative of mitochondrial number and
their ability to generate sufficient levels of ATP.
Although EPCs possessed 30% fewer copies of mtDNA
at 0 h, they accumulated similar levels to ECs by 6 h
and assumed a similar profile from then onwards (data
not shown). A similar outcome was observed for the
expression of the mtDNA-encoded gene cytochrome c
oxidase B (Cyt B), although levels were slightly higher
when tubule formation was most prevalent (6 h to 8 h;
Figure 3d-e).
Derivation of endothelial-like cells from ESCs can by
accelerated using EC-conditioned medium
To determine whether ESCs could give rise to
endothelial-like cells, we differentiated D3 ESCs over
28 days using spontaneous and directed methods
employing the hanging droplet technique. VEGFR2 was
detected in ESCs from day (D)1 onwards in both
approaches. VEGFR2 expression exceeded levels
observed in ECs after D4 in spontaneously-differen-
tiated ESCs (P < 0.01) and D2 in directed-differen-
tiated ESCs (P < 0.05; Figure 4a). Expression of
VEGFR2 in ESCs was significantly different between
differentiation treatments from D1 to D6. At D7 and
D14, directed- and spontaneously-differentiated ESCs,
respectively, expressed levels of VEGFR2 similar to
EPCs and this continued for the remainder of the cul-
ture period. VE-cadherin expression was low through-
out differentiation of ESCs, with expression not
reaching a level comparable to either EPCs or ECs in
either treatment before D28 (P > 0.05; Figure 4b).
There was no significant difference between differen-
tiation treatments. CD31 transcripts were present in
spontaneously- and directed-differentiated ESCs from
D1 with expression exceeding EC-equivalent levels at
D7 (P < 0.05) and D5 (P < 0.01), respectively (Figure
4c). CD31 expression in D21 and D28 ESCs (using
both treatments) was similar to that in EPCs. Further-
more, CD31 expression was significantly different
between ESC treatments from D2 to D14 (P < 0.05).
ICC confirmed that protein was present for all three
genes throughout differentiation for both treatments
(Figure 4d).
Differentiated ESCs demonstrate angiogenic potential
comparable to EPCs
As directed-differentiated ESCs more rapidly adopted
patterns of EPC-associated gene expression, we cultured
differentiating D7 ESCs on ECMatrix gel to assess their
angiogenic potential. The pattern of nodes formed by
D7 ESCs was similar to that of both EPCs and ECs (P <
0.05; Figure 5a). To this extent, the number of N1
nodes was maximal at 2 h and decreased throughout
the assay. Nevertheless, the number of N2, N3 and N4
nodes increased to their maximum towards the assay’s
mid point, whilst N5+ nodes were only evident at 8 h.
Branch length measurements of D7 ESCs, as for the
node data, were similar to EPCs and ECs (P < 0.05; Fig-
ure 5b). Mean length increased from 0 h to 6 h, with
maximal length observed at 6 h, and no branches were
evident by 14 h.
Figure 2 Angiogenic potential of EPCs and ECs. Tubule
formation of (A) EPCs and (B) ECs quantified by node counting.
Presented as mean node number ± SEM (n = 3); *P < 0.05 vs. EPC
nodes at same time-point. (C): Branch measurements, as mean
length per mm2 ± SEM (n = 3); †P < 0.05, ††P < 0.01 vs. EPC
branch length at same time-point.
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Figure 3 Gene expression during tubule formation. (A) VEGFR2, (B) VE-cadherin and (C) CD31 mean expression in assayed EPCs and ECs,
relative to 60% confluent ECs (± SEM; n = 3). Dotted line indicates expression in 60% confluent EPCs. Significant differences between cell types
indicated (*P < 0.05, **P < 0.01). CytB expression in (D) EPCs and (E) ECs, relative to 0 h. Columns with different letters are significantly different
(P < 0.05).
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Assayed D7 ESCs were analyzed by qPCR. Expression
of VEGFR2 in D7 ESCs increased significantly between
0 h and 2 h, and between 2 h and 4 h (Figure 5c).
VEGFR2 expression was maximal at 4 h and decreased
progressively from 6 h onwards. Expression of VE-cad-
herin in D7 ESCs was maximal at 4 h, although
expression was not significantly different from 0 h.
Expression decreased from 6 h to 14 h and was signifi-
cantly lower than 0 h between 10 h and 14 h (Figure
5d). Expression of CD31 in D7 ESCs was not signifi-
cantly different between 0 h and 8 h (Figure 5e),
decreasing significantly between 10 h and 14 h.
Figure 4 Endothelial differentiation of stem cells. (A) VEGFR2, (B) VE-cadherin and (C) CD31 expression in ESCs, relative to 60% confluent ECs
(± SEM; n = 3). Dotted line indicates expression in 60% confluent EPCs. Directed differentiation with ECCM, significant differences between
treatments indicated (*P < 0.05, **P < 0.01). (D): VEGFR2, CD133 and CD34 proteins in ECCM-treated ESCs. Scale bars = 10 μm.
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The incorporation of transplanted EPCs into pre-existing
endothelial tubules in vitro is dependent on the number
of cells transplanted
To determine whether EPC transplantation could
enhance the longevity of existing EC tubules, we added
EPCs to ECMatrix gel containing branching ECs that
had been in culture for 5 h. Transplantation was per-
formed with EPCs equal to 50% or 10% of the original
number of ECs. Following transplantation with 10%
equivalent EPCs, the greatest number of N1 nodes
occurred at 2 h, decreasing by 6 h (Figure 6a). However,
there was no significant decrease in N1 nodes between
6 h and 8 h. A progressive decrease in N1 nodes was
then seen between 10 h and 12 h, and by 14 h no N1
nodes were present. The maximum number of N2 and
N3 nodes occurred at 4 h (1 h prior to transplantation),
whilst N4 nodes were maximal at 6 h (1 h after trans-
plantation) and N5+ nodes were only evident at 6 h.
Nevertheless, in the 50% EPC-equivalent transplantation
assay, it is evident that the number of N1 nodes
decreased progressively between 2 h and 8 h (Figure
6b). However, an increase in N1 nodes was seen by 10 h
(P < 0.01), and between 10 h and 14 h the mean num-
ber of N1 nodes did not change significantly. The great-
est number of N2 nodes was recorded at 4 h (1 h prior
to transplantation) although N3 nodes were maximal at
8 h (3 h after transplantation). However, the mean num-
ber of N4 nodes, first evident at 4 h, increased signifi-
cantly from 4 h to 6 h (P < 0.05), then decreased
progressively between 8 h and 12 h. N5+ nodes were
first identified at 6 h, with no significant difference
between 6 h and 10 h with a slight reduction between
10 h and 14 h, whilst a significant decrease was
observed at 14 h (P < 0.05).
Transplantation had a beneficial effect on mean
branch length following both 50% and 10% transplanta-
tion. It increased from 2 h to 6 h (P < 0.01; Figure 6c)
with maximum values for both assays recorded at 6 h,
although this was slightly greater for the 50% transplan-
tation (P < 0.05). For both assays, branch length
decreased between 6 h and 14 h, with decreases at each
time-point being significantly lower following the 10%
transplantation (P < 0.01).
By labeling EPCs with fluorescent Qdots prior to
transplantation, their localisation into existing EC
tubules could be determined. With 50% transplantation,
Qdots were detected in high abundance throughout the
assay at all time-points (Figure 7a). Whilst Qdots were
not detected ubiquitously throughout the existing EC
network, between 6 h and 14 h tubule structures were
observed, composed entirely of Qdot-labelled EPCs. Fol-
lowing 10% transplantation, Qdots were randomly dis-
tributed within the existing EC tubule network (Figure
7b).
The effect of EPC transplantation on expression of
VEGFR2, VE-cadherin and CD31 was assessed using
qPCR. Prior to transplantation, expression patterns were
equivalent to ECs grown on ECMatrix gels without
transplantation. Following 50% transplantation, VEGFR2
expression increased significantly compared to non-
transplanted ECs (P < 0.05; Figure 8a) but decreased
continually following transplantation (6 h) until 14 h.
VE-cadherin expression following 50% transplantation
was not significantly different to non-transplanted ECs
until 8 h when greater expression was detected (P <
0.05; Figure 8b). Although expression decreased from 8
h to 14 h it was still significantly greater at each time-
point compared to control ECs (P < 0.05). CD31 expres-
sion was not altered significantly by 50% transplantation
until 6 h, when greater expression was seen compared
to control ECs (P < 0.05; Figure 8c). CD31 expression
was greater than non-transplanted ECs until 14 h, at
which time no significant difference was observed. 10%
EPC transplantation did not result in significant changes
in expression of VEGFR2, VE-cadherin or CD31 com-
pared to non-transplanted ECs (P > 0.05).
Discussion
Differences in endothelial-specific markers were
observed between the two stages of endothelial matura-
tion represented by the EPC and EC cell lines, with
both mRNA and protein expression confirming their
endothelial nature, in agreement with previous studies
[8,17]. When cultured on ECMatrix gel in vitro, both
EPCs and ECs formed complex endothelial tubule net-
works. It is generally assumed that tubule length and
node complexity correlate with angiogenic potential
[33]. Consequently, our data show that EPCs, which
form tubules of greater maximum length and complex-
ity, have a higher angiogenic potential than ECs. Having
demonstrated the capacity of EPCs to form tubules
structures in vitro, their transplantation potential was
investigated.
The effect of EPC transplantation on tubule formation
was variable, depending on the relative quantity of cells
used. When tubules were transplanted with a quantity
of EPCs equivalent to 50% of the number of ECs origin-
ally seeded onto the ECMatrix gel, the complexity of the
resultant network was significantly different to non-
transplanted EC-only controls. To this extent, the num-
ber of higher order nodes was greater after 5 h and
branch length was increased following transplantation.
As well as increasing complexity of the tubule network
through the conversion of N1s to more complex struc-
tures, such transplantation also increased tubule longev-
ity with nodes of all five types and branches being
observed at 14 h, compared to control assays in which
the network regressed after 12 h. In contrast, when EC
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tubules were transplanted with 10% EPCs no significant
differences were observed in either node counts or
branch lengths, suggesting little effect on either tubule
longevity or network complexity.
The increase in tubule longevity seen with 50% EPC
transplantation is consistent with previous investigations
into the role of circulating EPCs, where they are conti-
nually released from the bone marrow to maintain the
adult vasculature [34]. In addition to their role in vascu-
lar remodelling during angiogenesis, EPCs have also
been shown to play an important part in the repair of
defects in the EC layers of blood vessels and in the
Figure 5 Characterization of differentiating ESCs at D7. Tubule formation as (A) node number ± SEM (n = 3) and (B) tubule branch length ±
SEM (n = 3; *P < 0.05, **P < 0.01 vs. 2 h). (C) VEGFR2, (D) VE-cadherin and (E) CD31 mean expression in D7 ESCs (n = 3) relative to 60% confluent
ECs; *P < 0.05, **P < 0.01 vs. 0 h. Dotted line indicates expression in 60% confluent EPCs.
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maintenance of vascular wall integrity throughout adult
life [35]. The absence of a significant effect on tubule
formation with 10% transplantation is interesting
because, whilst EPC numbers increase during prolonged
angiogenic response, their low number in peripheral
blood of healthy adults may illustrate the active support
of endothelial cell turnover by EPCs. Nevertheless, aging
EPCs exhibit limited regenerative capacity and it may be
that regular, low level release of EPCs from bone mar-
row is more beneficial for continued maintenance of
endothelium [36]. Perhaps, if EPCs are indeed involved
in subtle vascular maintenance, their effect is too mod-
est to be demonstrated in the tubule formation assay.
For this reason, one might not expect 10% EPC trans-
plantation to have a dramatic effect on EC tubules in
the assay.
As with the functional readout described above, signif-
icant alteration in endothelial-specific gene expression
was only observed with 50% EPC transplantation. The
effect of EPCs on tubule growth, i.e. the quantitated
prolongation of complex nodal structures, is illustrated
by greater numbers of higher-order nodes persisting
throughout the assay period and the gene expression
data. The rate of decrease of VEGFR2, VE cadherin and
CD31 mRNA expression following transplantation is
less than in the non-transplanted assay. This suggests a
delay in downregulation of endothelial-specific gene
expression observed with assay progression. No signifi-
cant difference in expression was observed when EC
tubules were transplanted with 10% EPCs, compared to
non-transplanted ECs, further supporting the tubule
quantification data.
The outcomes of the two transplantation experiments
may be representative of two potential in vivo scenarios.
First, 10% transplantation simulates the low-level, conti-
nuing replenishment of maintenance EPCs into the cir-
culation. The phenotypic change in EPCs following 10%
transplantation was minor and their effect on existing
EC tubules was not significant. However, in 50% trans-
plantation, EPC gene expression was observed to change
dramatically and an obvious effect on EC tubule growth
was observed, suggesting a transition from quiescent cir-
culating EPCs to a more active, angiogenic phenotype.
This active phenotype may be beneficial in a second sce-
nario in which a large population of EPCs are mobilised,
either naturally or by drug administration, from the BM
in response to a greater vascular trauma, requiring a lar-
ger, more efficient EPC replenishment. Alternatively,
accumulation of EPCs by cytokine targetting may
require a threshold number before therapeutic effect
may be realised. Indeed, the beneficial effects of EPCs
have been demonstrated following the administration of
cytokines, such as SDF-1 [37] and G-CSF [38], to
increase the release of BM-resident EPCs into the circu-
lation. In these studies, the massive increase in mobi-
lised EPCs is contributing, by endothelial repopulation
and chemokine production, to resultant angiogenic
recovery, an effect reflected here in the 50% transplanta-
tion assay.
Our data shows that contact inhibition significantly
downregulates endothelial-specific gene expression in
Figure 6 In vitro EPC transplantation into EC tubules .
Transplantation using 10% (8 × 103) or 50% (4 × 104) EPCs at 5 h.
Node counts of (A) 10% and (B) 50% transplantation (± SEM, n = 3).
*P < 0.05 and **P < 0.01 vs. 10% EPC transplantation at same time-
point. (C): Mean tubule length per mm2 (±SEM; n = 3). Significant
differences between transplantations indicated (†P < 0.05, ††P <
0.01).
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Figure 7 Localisation of EPCs following in vitro transplantation.
Transplantation into EC tubules performed using 50% (4 × 104) or
10% (8 × 103) Qdot-labelled EPCs at 5 h. EPC localisation in (A) 50%
and (B) 10% transplantation assays, showing bright field,
fluorescence and merged images from 6-14 h at 2 h intervals. Scale
bars = 500 μm.
Figure 8 Endothelial expression following EPC transplantation.
(A) VEGFR2, (B) VE-cadherin and (C) CD31 expression in 50% and
10% transplantation assays, relative to expression in 60% confluent
ECs. Dotted line indicates expression in 60% confluent EPCs.
Significant differences between transplantations indicated (*P < 0.05,
**P < 0.01).
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static EPCs. EPCs intercalating into sites of vessel
growth, becoming increasingly contact-inhibited, may
have their capacity for neovascularisation affected in this
way. If low-level circulating EPCs are subject to rela-
tively low confluency in the bloodstream, the effect of
contact inhibition may be reduced. If so, using 60% con-
fluent EPCs (rather than 80% or 100%), as undertaken
in our transplantation experiments, may better replicate
the microenvironment of EPCs released into the
circulation.
Using gene expression analysis, it was established that
ESCs demonstrated endothelial phenotypes with different
rates of differentiation. Levels of VEGFR2 and CD31
mRNA transcripts in directed-differentiated ESCs
increased at a faster rate compared to spontaneously-dif-
ferentiated ESCs. VEGFR2 expression in ECCM-treated
ESCs reached a level equivalent to ECs two days earlier
than in spontaneously-differentiated ESCs (D2 vs. D4),
and an EPC-comparable level eight days earlier (D6 vs.
D14). An EC-equivalent level of CD31 expression was
observed two days earlier in ESCs treated with ECCM (D5
vs. D7), reaching an EPC-equivalent seven days earlier
(D14 vs. D21). In contrast, the effect of ECCM on VE-cad-
herin expression was not significant: neither sponta-
neously- and directed-differentiated ESCs demonstrated
expression similar to EPCs or ECs before D28. Unlike
VEGFR2 and CD31, VE-cadherin expression was deter-
mined to be greater in ECs than in EPCs, and is consid-
ered indicative of later stages of endothelial maturation
[39]. Thus, it is possible that more significant changes in
VE-cadherin expression may have been seen if differentia-
tion had been continued beyond D28, at a much later
stage of endothelial development. Whilst ECCM has been
demonstrated to improve endothelial differentiation rate,
resulting in earlier onset of expression, the final expression
pattern is comparable to naturally and spontaneously dif-
ferentiated cells [40,41]. Our data supports this view,
showing directed differentiation of ESCs using ECCM has
the effect of significantly increasing the rate of develop-
ment from a pluripotent stem cell to an endothelial-like
progenitor cell, but does not affect the final phenotype
(based on expression at D28).
The action of the ECCM is related to the particular
combination of paracrine factors released into the med-
ium during conditioning, such as VEGF and Ang-1
[42,43]. Furthermore, its effect can be augmented by
inclusion of additional factors, such as stem cell factor
and erythropoietin, modifying the efficacy of directed
differentiation [40]. However, the precise combination of
factors necessary for efficient directed differentiation is
not yet understood and potentially important factors
remain unknown [44]. Consequently, the mechanism
controlling the effect of ECCM on cellular expression
remains unclear. ESC-derived (D7) EPCs demonstrated
in vitro tubule formation patterns similar to natural
EPCs when cultured on ECMatrix gel. In addition,
endothelial-specific gene expression in ESC-derived
EPCs during tubule formation was found to be signifi-
cantly similar to natural EPCs over the course of the
tubule formation assay, further suggesting an equivalent
endothelial phenotype and angiogenic potential.
Conclusions
As a transplanted cell population, the angiogenic poten-
tial of EPCs is both cumulative and beneficial. We sug-
gest that effective EPC transplantation relies on both the
upregulation of the angiogenic phenotype of each indivi-
dual cell and an increase in cell number overall to pro-
duce a significant beneficial effect. Small numbers of
transplanted EPCs exhibit limited angiogenic activity in
vitro whilst a larger population shows a significant tran-
sition in phenotype and a much greater angiogenic
potential overall, demonstrating a differential response
to vascular maintenance or major injury. We have also
demonstrated that cells of a comparable phenotype and
angiogenic potential to EPCs, which can be difficult to
expand easily in vitro, can be efficiently derived by the
differentiation of ESCs. Ultimately, with the proposed
therapeutic benefits of EPCs, easily-maintained, ESC-
derived EPCs may have potential as a rapidly-expand-
able and fully characterised alternative to natural EPCs
for angiogenic transplantation therapy.
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